Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Fisher & Paykel Healthcare Corporation Limited (FPH.NZ)
Auckland, NZ
Operating globally, Fisher & Paykel Healthcare Corporation Limited specializes in the development, manufacturing, and marketing of a wide array of medical device products and systems. These solutions are primarily utilized for acute and chronic respiratory care, during surgical procedures, and in the treatment of obstructive sleep apnea (OSA) within both hospital and home environments. Key offerings include the Airvo 2, a humidified nasal high flow system; Optiflow, for nasal high flow therapy; and the F&P 850 System, which facilitates noninvasive and invasive ventilation. The company also provides a comprehensive range of infant respiratory products, encompassing devices for resuscitation, continuous positive airway pressure (CPAP) therapy, and nasal high flow therapy. Its extensive hospital product portfolio features humidification equipment, breathing circuits, chambers, various masks, nasal cannulas, surgical components, and different interfaces and accessories. For homecare, Fisher & Paykel Healthcare supplies masks, CPAP devices, data management software, humidifiers, and related accessories. Established in 1934, the company is headquartered in Auckland, New Zealand.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.63% | +11.40% | +3.75% | -8.95% | -2.79% | -1.11% | +3.46% | +55.67% | +18.96% | +265.98% | +8,585.44% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 4 | 0 |
| Hold | 6 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%+25.1% ★ Q1'26: +43.3% (vs Q1'24)
-
EPS growth Medical - Instruments & Supplies: +16.3%+33.4% ★ Q1'26: +909.4% (vs Q1'24)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+21.8% ★ Q1'26: +24.0% (vs Q1'24)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+28.5% ★ Q1'26: +29.8% (vs Q1'24)
-
ROIC Medical - Instruments & Supplies: +6.0%+27.5% ★ Q1'26: +60.2% (vs Q1'24)
-
Share dilution Medical - Instruments & Supplies: +0.1%+0.1% Q1'26: -0.4% (vs Q1'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×0.18× ★ Q1'26: 0.08× (vs Q1'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 16 Rev. Ana. 9 EPS Ana. |
Mar 2027 16 Rev. Ana. 9 EPS Ana. |
Mar 2028 15 Rev. Ana. 8 EPS Ana. |
Mar 2029 3 Rev. Ana. 3 EPS Ana. |
Mar 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
636.00M
est: 671.82M (-5.3%)
|
736.42M
est: 892.13M (-17.5%)
|
797.79M
est: 977.53M (-18.4%)
|
908.35M
est: 1.05B (-13.1%)
|
1.03B
est: 1.12B (-8.3%)
|
1.24B
est: 1.27B (-2.4%)
|
1.79B
est: 2.24B (-19.8%)
|
1.52B
est: 1.83B (-17.2%)
|
1.48B
est: 1.69B (-12.6%)
|
1.61B
est: 1.74B (-7.1%)
|
1.87B
est: 2.02B (-7.3%)
|
2.30B
2.27B – 2.32B
+13.9% YoY
|
2.56B
2.49B – 2.63B
+11.2% YoY
|
2.84B
2.73B – 3.02B
+11.3% YoY
|
3.12B
3.07B – 3.17B
+9.7% YoY
|
3.37B
3.26B – 3.52B
+7.9% YoY
|
| EBITDA |
188.86M
est: 211.45M (-10.7%)
|
216.01M
est: 280.79M (-23.1%)
|
253.54M
est: 307.67M (-17.6%)
|
292.99M
est: 329.17M (-11.0%)
|
316.79M
est: 352.76M (-10.2%)
|
424.11M
est: 400.17M (+6.0%)
|
744.36M
est: 704.16M (+5.7%)
|
559.28M
est: 576.96M (-3.1%)
|
404.04M
est: 533.01M (-24.2%)
|
337.58M
est: 546.20M (-38.2%)
|
576.01M
est: 635.21M (-9.3%)
|
723.82M
713.20M – 729.04M
+13.9% YoY
|
804.53M
784.55M – 827.63M
+11.2% YoY
|
895.26M
859.75M – 951.29M
+11.3% YoY
|
981.67M
965.99M – 997.34M
+9.7% YoY
|
1.06B
1.02B – 1.11B
+7.9% YoY
|
| EBIT |
157.61M
est: 173.12M (-9.0%)
|
184.34M
est: 229.89M (-19.8%)
|
217.70M
est: 251.90M (-13.6%)
|
250.98M
est: 269.50M (-6.9%)
|
276.81M
est: 288.81M (-4.2%)
|
364.69M
est: 327.63M (+11.3%)
|
666.08M
est: 576.51M (+15.5%)
|
470.55M
est: 472.37M (-0.4%)
|
311.81M
est: 436.39M (-28.5%)
|
232.78M
est: 447.19M (-47.9%)
|
471.54M
est: 520.06M (-9.3%)
|
592.61M
583.92M – 596.88M
+13.9% YoY
|
658.69M
642.33M – 677.60M
+11.2% YoY
|
732.97M
703.90M – 778.84M
+11.3% YoY
|
803.71M
790.88M – 816.55M
+9.7% YoY
|
867.12M
838.80M – 907.51M
+7.9% YoY
|
| Net Income |
111.76M
est: 118.67M (-5.8%)
|
129.04M
est: 163.19M (-20.9%)
|
155.20M
est: 190.95M (-18.7%)
|
179.13M
est: 206.44M (-13.2%)
|
200.58M
est: 223.27M (-10.2%)
|
279.85M
est: 292.51M (-4.3%)
|
482.79M
est: 616.02M (-21.6%)
|
348.36M
est: 412.51M (-15.5%)
|
233.18M
est: 278.07M (-16.1%)
|
121.57M
est: 263.70M (-53.9%)
|
349.03M
est: 377.20M (-7.5%)
|
466.27M
455.51M – 480.25M
+23.6% YoY
|
538.01M
516.29M – 600.95M
+15.4% YoY
|
631.08M
597.69M – 747.84M
+17.3% YoY
|
745.54M
722.48M – 768.60M
+18.1% YoY
|
74.79M
71.61M – 79.32M
-90.0% YoY
|
| SGA |
178.66M
est: 169.23M (+5.6%)
|
217.99M
est: 224.73M (-3.0%)
|
247.10M
est: 246.24M (+0.3%)
|
259.27M
est: 263.45M (-1.6%)
|
291.86M
est: 282.33M (+3.4%)
|
329.23M
est: 320.28M (+2.8%)
|
365.27M
est: 563.57M (-35.2%)
|
363.34M
est: 461.76M (-21.3%)
|
402.37M
est: 426.59M (-5.7%)
|
451.81M
est: 437.15M (+3.4%)
|
494.49M
est: 508.39M (-2.7%)
|
579.30M
570.81M – 583.48M
+13.9% YoY
|
643.90M
627.91M – 662.39M
+11.2% YoY
|
716.52M
688.09M – 761.35M
+11.3% YoY
|
785.67M
773.13M – 798.21M
+9.7% YoY
|
847.66M
819.97M – 887.14M
+7.9% YoY
|
| EPS |
0.20
est: 0.20 (+0.6%)
|
0.29
est: 0.28 (+4.4%)
|
0.33
est: 0.32 (+1.0%)
|
0.35
est: 0.35 (+0.1%)
|
0.39
est: 0.38 (+1.9%)
|
0.50
est: 0.50 (+0.9%)
|
0.91
est: 1.04 (-12.8%)
|
0.65
est: 0.70 (-7.0%)
|
0.43
est: 0.47 (-9.3%)
|
0.23
est: 0.45 (-48.5%)
|
0.59
est: 0.62 (-4.3%)
|
0.79
0.77 – 0.81
+28.5% YoY
|
0.91
0.87 – 1.02
+15.1% YoY
|
1.07
1.01 – 1.27
+16.9% YoY
|
1.25
1.22 – 1.30
+17.3% YoY
|
0.13
0.12 – 0.13
-89.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-26 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-25 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-22 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-21 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-20 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-19 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-18 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-15 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-14 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-13 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-12 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-01 | B | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | B | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | B | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | B | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | B | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | B | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | B | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | B | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | B | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | B | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | B | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-15 | B | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Lewis G. Gradon | MD, Chief Executive Officer & Executive Director | 3M | male |
| Andy Niccol | Chief Operating Officer | — | male |
| Daniel Adolph | Head of Investor Relations | — | male |
| Jonathan Rhodes | Vice President Network Design, Facilities, Infrastructure & Sustainability | — | male |
| Justin Callahan | Vice President of Sales & Marketing | — | male |
| Karen Knott | General Manager of Corporate Communications | — | — |
| Lyndal York | Chief Financial Officer | — | female |
| Nicola Talbot | Vice President of Human Resources | — | female |
| Andrew Somervell | Vice President of Products & Technology | — | — |
| Raelene Leonard | Company Secretary & General Counsel | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for FPH.NZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
